Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 5Expanded_access 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Thyroid Cancer, Papillary 1Pancreatic Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Medullary 1Breast Neoplasms 1

Interventions

3-Iodobenzylguanidine 6fluorodopa F 18 2Ga(III)-DOTATOC 2surufatinib 1selpercatinib 1pegfilgrastim 1lutetium Lu 177 dotatate 1gallium Ga 68 dotatate 1Vorinostat 1Potassium Iodide 1Granulocyte Colony-Stimulating Factor 1Gallium-68 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × selpercatinib × Endocrine × Clear all
NCT03906331 2025-01-17

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Eli Lilly and Company

Approved for marketing
BreastEndocrineGastrointestinalHead & NeckThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Pancreatic Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡